Skip to main content
Premium Trial:

Request an Annual Quote

Europe, EMBL Pledge Continued Partnership

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – The European Commission and the European Molecular Biology Laboratory (EMBL) have signed a memorandum of understanding to continue their ongoing partnership to support and develop Europe's life sciences research efforts.

The MOU was formally signed today at EMBL's main lab in Heidelberg, Germany.

Under the agreement, the EC and EMBL have agreed to consolidate and continue to develop the European Research Area, particularly in the areas of research programming, training and the mobility of researchers, research infrastructures, managing intellectual property, and international collaboration.

The EC is EMBL's largest external funder, providing it with €12.4 million ($17.3 million) in support in 2010. The two entities have collaborated since 1995.

"EMBL's excellent research is fundamental to our understanding of life itself and will underpin many of the advances we will see in medicine and other domains in the years to come," Máire Geoghegan-Quinn, European Commissioner for Research, Innovation and Science, said in a statement.

EMBL was formed to promote molecular biology across Europe, which it does by supporting basic molecular biology research and new technologies, providing facilities, services, and training, and by providing technology transfer support.

Governed by a council and supported by 20 member states, EMBL has major facilities in Heidelberg and Hamburg, Germany; Hinxton, UK; Grenoble, Switzerland; and in Monterotondo, Italy.

"As the European intergovernmental institution for molecular life sciences, EMBL has extensive scientific and technical expertise coupled with years of success empowering life scientists from European countries to conduct cutting-edge research at state-of-the art research infrastructures," said EMBL Director General Iain Mattaj.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.